Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
Merz C, Strecker A, Sykora J, Hill O, Fricke H, Angel P, Gieffers C, Peterziel H. Merz C, et al. Anticancer Drugs. 2015 Aug;26(7):716-27. doi: 10.1097/CAD.0000000000000237. Anticancer Drugs. 2015. PMID: 25850884 Free PMC article.
Because APG101 is not cytotoxic to tumour cells in vitro, we postulated that the anti-invasive function of APG101 is the main mechanism of action for this compound. ...Invasion was restored in CD95L knockdown cells upon the additio …
Because APG101 is not cytotoxic to tumour cells in vitro, we postulated that the anti-invasive function of AP
Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.
Blaes J, Thomé CM, Pfenning PN, Rübmann P, Sahm F, Wick A, Bunse T, Schmenger T, Sykora J, von Deimling A, Wiestler B, Merz C, Jugold M, Haberkorn U, Abdollahi A, Debus J, Gieffers C, Kunz C, Bendszus M, Kluge M, Platten M, Fricke H, Wick W, Lemke D. Blaes J, et al. Mol Cancer Res. 2018 May;16(5):767-776. doi: 10.1158/1541-7786.MCR-17-0563. Epub 2018 Feb 16. Mol Cancer Res. 2018. PMID: 29453321 Free article.
A phase II clinical trial on relapsed glioblastoma patients demonstrated that targeted inhibition of CD95 signaling via the CD95 ligand (CD95L) binding and neutralizing Fc-fusion protein APG101 (asunercept) prolonged patient surviv …
A phase II clinical trial on relapsed glioblastoma patients demonstrated that targeted inhibition of CD95 signaling via the …